Since LAR has the convenience of a once-weekly injection and can carry premium pricing, the bullish analysts believe the drug can become a strong seller since it will be the most convenient GLP-1 on the market until potential approval of its competing drugs, Taspoglutide and Syncria in 2012/2013.  The analysts view AMLN’s partnership with Takeda Pharmaceutical Company Limited for obesity program as positive as it is expected to offset cash burn and bring commercial leverage to the obesity programs.